ALLTARF INVESTMENTS

We are bringing the cure of cancer closer
THESIS
ALLTARF INVESTMENTS
is launching a $250M VC fund to drive early-stage and more well-developed stage Biotech Startups, focused on innovative cancer treatment solutions, as well as to develop the venture ecosystem in the US, Europe and MENA region. Our team is a rare combination of Ph.D. scientists, tech entrepreneurs, industry opinion leaders, and M&A dealmakers with an exceptional scientific background and investment experience including work in teams, who identified and raised multiple unicorns.
MANAGEMENT TEAM - GENERAL PARTNERS
  • Colin Bier
    General Partner
    • 30+ yrs experience in pharma/biotech development
    • NCI Fellow
    • Dr. Douglas James Fellow and Medical Research Council Fellow, Department of Pathology, McGill University
    • Extensive worldwide regulatory experience and bio-management
    • Consulted to more than 60 biotech/pharma companies
    • Conducted more than 140 due diligence investigations
    • Sr. Scientific/Medical Advisor to two Venture funds
    • Managing Director & Consultant Toxicologist, ABA BioResearch, Inc
  • Yves Decadt
    General Partner
    • Masters in Pharmacology (Brussels), Bio-Engineering (Ghent), Industrial Business Administration (Ghent)
    • 18 years in Johnson&Johnson pharma, incl 10 years in global BD (Belgium, USA, Switzerland)
    • Co-founder and CEO at BioLingus (Switzerland)
    • Senior Management/Board Advisor at Medimetrics, Stragen, H-BIO
    • Executive Advisor to NEOM Biotech/Healthtech
  • Alexander Khorokhorin
    General Partner
    • Ph.D. in World Economy, EMBA Kingston (UK)
    • 15 years in Consulting, Marketing, Engineering, and Investment Banking (Samsung, Wood Group, BP)
    • Closed deals for ~$0,7bn
    • 10 years investing in Biotech (ARNA, PCSC, Fosco-BIO, Angelico Ventures)
    • Partner of 3,000+ member tech founders` community
SAB MANAGEMENT TEAM
  • Scott Kahn
    Venture Partner
    • Ph.D. in Biochemistry and Molecular Biology
    • Founder, Alykomed Global Solutions LLC Chairman
    • Biomarkers Council - International Cancer Advocacy Network Senior Scientific Advisor, Progenicyte Therapeutics; Advisor
    • Intelligence Ventures: Advisor
    • Herbert Irving Comprehensive Cancer Center- Columbia University, NY
    • Japan Agency for Medical Research and Development (AMED)
    • CSO of the Oncostem Biotherapeutics, LLC
  • Kenneth J. Gorelick
    Chief Medical Officer
    • MD, FACP, FCCP
    • > 30 years' experience in drug and biotechnology development, with NDAs, BLAs, INDs, Orphan Drugs, Fast Track, regulatory interactions at all levels.
    • Multiple therapeutic areas including oncology, anti-infectives, anti-virals, biodefense, hematology
    • Venture Partner in NGN Capital for 18 years
    • Chief Medical Officer in Pi Pharma for 7 years
    • Université de Paris (Medicine), University at Buffalo (Biochemistry)
EXTENSIVE DD IN PARTNERSHIP WITH PREQUALIFIED CROS
• Strong relationships with the reputable CROs in Eastern Europe will make it possible to launch First in Humans FDA/EMA capable Express Investigator Initiated Trials (IITs) 6-10 months for a reasonable price within ALLTARF INVESTMENTS approved DD process, to justify safety and efficacy models. This will be done prior to spending a full-scale Phase-I FDA/EMA trials budget for the best Candidates, shortlisted by Advisory Board and AI/ML engines in Drug Discovery and Drug Development.
• The Best selected candidates patients within IIT during Phase-I full-scale trials, will be subject to Post-trial monitoring for 1-2 years and the stability of the treatment effects will justify entering a Phase-II FDA/EMA trials in addition to successful Phase-I trial outcomes.
• This DD model will provide substantial scientific evidence for a better predisposition of candidates to pass successfully Phase-I and Phase-II FDA/EMA Human trials.
VALUE ADD
We invest time and expertise in the most promising HealthTech startups to help them with:
MORE INFO...
We use cookies to provide the best site experience.
Ok, don't show again
DISCLAIMER

This presentation is produced by ALLTARF INVESTMENTS and/or its affiliates (hereafter "IV") for information purposes only. No representation or warranty, expressed or implied, is made or given by IV as to the accuracy, completeness or fairness of the information or opinions contained in this presentation. In particular, no representation or warranty is made that any projection, forecast, calculation, forward-looking statement, assumption or estimate contained in this presentation should or will be achieved. Furthermore, all opinions and data used in this document are subject to change without prior notice. With respect to any performance data contained herein, the recipient of this presentation should bear in mind that past performance is not indicative of future performance, and there can be no assurance that any future fund managed or sponsored by IV will achieve comparable results. The information contained in this presentation does not constitute investment, legal, tax or accounting advice. Recipients of this presentation should conduct their own due diligence and other enquiries in relation to such information and consult with their own professional advisors as to the accuracy and application of the information contained in this presentation. The information provided in this presentation is not legally binding and it does not constitute an offer or invitation to enter into any type of financial transaction. Neither this presentation nor any copy thereof may be sent, taken into or distributed in the United States or to any U. S. person (within the meaning of Regulation Sunder the US Securities Act of 1933, as amended). It may not be reproduced, neither in part nor in full, without the written permission of IV

We are bringing the cure of cancer closer
Made on
Tilda